Member of the Association of American Physicians
His scientific interests lie mostly in Molecular biology, Cell biology, Immunology, Haematopoiesis and Cancer research. His Molecular biology research includes elements of CXCL2, Complementary DNA, FOXD3, Enhancer and DNA-binding domain. His biological study spans a wide range of topics, including CXCL14 and Genetics.
His Haematopoiesis research is multidisciplinary, incorporating perspectives in Progenitor cell, Endothelial stem cell, Internal medicine and Endocrinology. His work deals with themes such as Myeloid, Chemotaxis and Chemokine, which intersect with Progenitor cell. His work carried out in the field of Cancer research brings together such families of science as BRCA2 Protein, STAT3, Synthetic lethality and Mutation.
His primary areas of study are Molecular biology, Cell biology, Cancer research, DNA repair and DNA. His Molecular biology research includes themes of Mutation, Gene, DNA-binding protein, Enhancer and DNA-binding domain. His specific area of interest is Cell biology, where Robert Hromas studies Haematopoiesis.
Robert Hromas combines subjects such as Immunology, Myeloid, Cytokine, Bone marrow and Progenitor cell with his study of Haematopoiesis. His study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Cancer, Carcinogenesis, Synthetic lethality and PARP1. His research investigates the link between DNA repair and topics such as Homologous recombination that cross with problems in Genome instability.
The scientist’s investigation covers issues in Cancer research, DNA repair, DNA damage, Homologous recombination and Cell biology. His Cancer research study integrates concerns from other disciplines, such as Cancer cell, Cancer, BAP1, Synthetic lethality and Paraganglioma. His studies deal with areas such as Replication protein A and DNA replication as well as DNA repair.
His study in the field of RAD51 also crosses realms of Recombinase. Robert Hromas is interested in Myelopoiesis, which is a branch of Cell biology. His Molecular biology research extends to the thematically linked field of DNA.
His main research concerns Homologous recombination, DNA repair, Genome instability, Cancer research and Cell biology. The study incorporates disciplines such as Suppressor and DNA replication in addition to Homologous recombination. His DNA replication study contributes to a more complete understanding of Genetics.
His studies in Genome instability integrate themes in fields like Nucleotide excision repair, DNA Repair Pathway, Synthetic lethality and DNA End-Joining Repair. His research integrates issues of Cancer cell, Leukemia and In vivo in his study of Cancer research. Robert Hromas applies his multidisciplinary studies on Cell biology and Ribose in his research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Transcription factors, normal myeloid development, and leukemia.
Daniel G. Tenen;Robert Hromas;Jonathan D. Licht;Dong-Er Zhang.
Blood (1997)
Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production.
Trevor Starnes;Michael J. Robertson;George Sledge;Stephanie Kelich.
Journal of Immunology (2001)
Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis.
Trevor Starnes;Hal E. Broxmeyer;Michael J. Robertson;Robert A Hromas.
Journal of Immunology (2002)
Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells.
Rafat Abonour;David A. Williams;Lawrence Einhorn;Kristin M. Hall.
Nature Medicine (2000)
Drug Repurposing from an Academic Perspective.
Tudor I. Oprea;Julie E. Bauman;Cristian G. Bologa;Tione Buranda.
Drug Discovery Today: Therapeutic Strategies (2011)
PLAB, a novel placental bone morphogenetic protein.
Robert Hromas;Matthew Hufford;Jill Sutton;Dawei Xu.
Biochimica et Biophysica Acta (1997)
Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining
Sheema Fnu;Elizabeth A. Williamson;Leyma P. De Haro;Mark Brenneman.
Proceedings of the National Academy of Sciences of the United States of America (2011)
Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1
R Hromas;A Orazi;RS Neiman;R Maki.
Blood (1993)
Genesis, a winged helix transcriptional repressor with expression restricted to embryonic stem cells.
Jill Sutton;Robert Costa;Michael Klug;Loren Field.
Journal of Biological Chemistry (1996)
A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells.
R Hromas;S J Collins;D Hickstein;W Raskind.
Journal of Biological Chemistry (1991)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Indiana University
Indiana University
Indiana University
The University of Texas Health Science Center at San Antonio
University of Florida
University of Michigan–Ann Arbor
Indiana University
University of Florida
University of New Mexico
University of New Mexico
TU Wien
Central South University
Peter the Great St. Petersburg Polytechnic University
RMIT University
University of Amsterdam
Leiden University
Tel Aviv University
University of Oslo
Clark University
Memorial Sloan Kettering Cancer Center
Technical University of Munich
Complutense University of Madrid
University of Jyväskylä
The University of Texas MD Anderson Cancer Center
University of Wisconsin–Madison
University of Huddersfield